Publication analysis · Module 3
BELIEVE: body composition is not the same as function
BELIEVE was a randomized phase 2 trial in 507 adults with obesity, excluding diabetes. It compared bimagrumab, semaglutide, combinations and placebo over 48 weeks, followed by an open-label extension. Bimagrumab is an investigational monoclonal antibody, not a peptide agonist.
Original publication
Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial
DOI 10.1038/s41591-026-04204-0 · PMID 41772149 · Citation pending verification
Educational information for healthcare professionals and the general public. Not individual medical advice, diagnosis, treatment, or a recommendation to use a compound.
BELIEVE was a randomized phase 2 trial in 507 adults with obesity, excluding diabetes. It compared bimagrumab, semaglutide, combinations and placebo over 48 weeks, followed by an open-label extension. Bimagrumab is an investigational monoclonal antibody, not a peptide agonist.
The findings support further study of weight and body composition. Preserving lean mass on DXA does not by itself establish better strength or daily function. Combination research should retain its trial phase and comparator; it should not be presented as a treatment standard or a validated commercial stack.
References
Bibliographic sources shown for transparency. Citation verification pending; no citation is marked verified.
Related resources
Publication analysis · Module 3
SURMOUNT-1: interpreting a multigroup obesity trial
SURMOUNT-1 randomized 2,539 adults with overweight or obesity, excluding diabetes, to three weekly tirzepatide groups or placebo for 72 weeks. Mean weight changes were −15.0%, −19.5%, and −20.9% in the 5-, 10-, and 15-mg study groups, respectively, versus −3.1% with placebo. These amounts identify trial groups, not an administration recommendation.
Publication analysis · Module 3
STEP 9: weight, knee pain and function
STEP 9 randomized 407 adults with obesity and painful knee osteoarthritis to semaglutide or placebo for 68 weeks, with lifestyle counseling in both groups. Weight and WOMAC pain scores improved more with semaglutide; physical function also improved. Gastrointestinal problems were the most common reason for treatment discontinuation.
Publication analysis · Module 3
Semaglutide and alcohol: an early randomized trial
A nine-week phase 2 trial randomized 48 adults with alcohol use disorder who were not seeking treatment to semaglutide or placebo. Laboratory alcohol consumption and some weekly drinking and craving measures improved. Average drinks per calendar day and the number of drinking days did not significantly change.